Changeflow GovPing Healthcare & Life Sciences Sotalol Hydrochloride 150mg/10ml NDA 022306
Routine Notice Added Final

Sotalol Hydrochloride 150mg/10ml NDA 022306

Favicon for www.accessdata.fda.gov FDA Orange Book — New Patent Listings
Published
Detected
Email

Summary

Altathera Pharmaceuticals LLC received FDA approval for Sotalol Hydrochloride (150mg/10ml, 15mg/ml) solution for intravenous administration under NDA 022306, approved July 2, 2009. The product is listed as both a Reference Listed Drug and Reference Standard with Prescription marketing status. Patent and exclusivity information is available through the linked Orange Book patent info page.

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Orange Book — New Patent Listings for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

The FDA Orange Book now includes a listing for Sotalol Hydrochloride 150mg/10ml (15mg/ml) solution for intravenous use, approved under NDA 022306 to Altathera Pharmaceuticals LLC. The product holds Reference Listed Drug and Reference Standard designations, indicating it may serve as a basis for Abbreviated New Drug Applications (ANDAs) seeking approval of generic versions. Affected parties seeking to reference this product in generic applications should consult the linked patent and exclusivity information page to determine any blocking patents or exclusivity periods.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Home | )

Product Details for NDA 022306

SOTALOL HYDROCHLORIDE (SOTALOL HYDROCHLORIDE)
150MG/10ML (15MG/ML)
Marketing Status:
Prescription
Active Ingredient: SOTALOL HYDROCHLORIDE
Proprietary Name: SOTALOL HYDROCHLORIDE
Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS
Strength: 150MG/10ML (15MG/ML)
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code:
Application Number: N022306
Product Number: 001
Approval Date: Jul 2, 2009
Applicant Holder Full Name: ALTATHERA PHARMACEUTICALS LLC
Marketing Status: Prescription
Patent and Exclusivity Information

Get daily alerts for FDA Orange Book — New Patent Listings

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
July 2nd, 2009
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug approval Patent listing Generic drug reference
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when FDA Orange Book — New Patent Listings publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!